Trabectedin in Soft Tissue Sarcomas

Petek, Bradley J.; Loggers, Elizabeth T.; Pollack, Seth M.; Jones, Robin L.

doi:10.3390/md13020974

Cited by 18 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 For example, trabectedin, isolated from the sea squirt Ecteinascidia turbinata and subsequently prepared synthetically, was recently approved in Europe for the treatment of soft-tissue sarcoma (Yondelis). 2 …”

Section: Introductionmentioning

confidence: 99%

Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

et al. 2015

View full text Add to dashboard Cite

Docking studies of tubulin-targeting C2-substituted 7-deazahypoxanthine analogues of marine alkaloid rigidins led to the design and synthesis of compounds containing linear C2-substituents. The C2-alkynyl analogue was found to have double- to single-digit nanomolar antiproliferative IC50 values and showed statistically significant tumor size reduction in a colon cancer mouse model at nontoxic concentrations. These results provide impetus and further guidance for the development of these rigidin analogues as anticancer agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Adverse drug reactions of grade III and IV occur only in about 10% of treated cases. The most common grade III and IV adverse reactions are: reversible elevation of aminotransferases and myelotoxicity, in particular neutropenia and anaemia [4,23]. Transient increase of transaminases typically occurs several days after administration of trabectedin and it usually resolves spontaneously after about 15 days.…”

Section: Side Effectsmentioning

confidence: 99%

Trabectedin in the treatment of patients with soft tissue sarcoma

Koseła-Paterczyk¹,

Rutkowski²

2018

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are rare malignant tumours derived from connective tissue. They constitute about 1% of malignancies occurring in adults. We distinguish over 60 subtypes of soft tissue sarcoma, each with a unique clinical course and a diversified response to systemic treatment. The prognosis for patients with locally advanced, unresectable or metastatic disease remains poor. For years, doxorubicin-used alone or in combination with ifosfamide-has been the basis of treatment for these patients. Trabectedin is a relatively new molecule registered in the treatment of patients diagnosed with STS. The drug was originally obtained from marine tunicates (Ecteinascidia turbinata), currently it is obtained semi-synthetically. So far, a number of potential mechanisms of trabectedin have been described, including DNA-binding, disruption of DNA repair mechanisms and cell cycle, as well as effects on transcription factors and the tumour microenvironment. The aim of the following review is to summarize the current knowledge on the efficacy and safety of trabectedin in the treatment of patients diagnosed with STS.

show abstract

“…Another review on trabectedin is provided by Petek and colleagues from the USA. The authors discuss the mechanism of action of the drug, and its activity and development in the treatment of soft tissue sarcomas [ 13 ]. Stonik and Fedorov from the Russian Federation provide an up-date on marine cancer preventive small-molecule compounds .…”

Section: Review Articlesmentioning

confidence: 99%

Marine Compounds and Cancer: Where Do We Stand?

Dyshlovoy

Honecker

2015

Marine Drugs

View full text Add to dashboard Cite

In Western countries, cancer is among the most frequent causes of death. Despite striking advances in cancer therapy, there is still an urgent need for new drugs in oncology. Current development favors so called “targeted agents” or drugs that target the immune system, i.e., therapeutic antibodies that enhance or facilitate an immune response against tumor cells (also referred to as “checkpoint inhibitors”). However, until recently, roughly 60% of drugs used in hematology and oncology were originally derived from natural sources, and one third of the top-selling agents are either natural agents or derivatives [1]. There is justified hope for the discovery and development of new anticancer agents from the marine environment. Historically, this habitat has proven to be a rich source of potent natural compounds such as alkaloids, steroids, terpenes, macrolides, peptides, and polyketides, among others. Interestingly, marine agents and cancer treatment have had a special relationship from the beginning. One of the first marine-derived compounds, discovered in 1945 that was later developed into a clinically used drug, was spongothymidine [2–4], which was the lead compound for the discovery of cytarabine [5]. Until today, cytarabine remains one of the most widely used agents in the treatment of acute myeloid leukemia and relapsed aggressive lymphomas. [...]

show abstract

Trabectedin in Soft Tissue Sarcomas

Cited by 18 publications

References 43 publications

Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

Trabectedin in the treatment of patients with soft tissue sarcoma

Marine Compounds and Cancer: Where Do We Stand?

Contact Info

Product

Resources

About